What IQ Consortium does

IQ Consortium is a not-for-profit industry consortium of 58 pharmaceutical and biotechnology companies, founded in 2010 and headquartered at 1500 K St. NW in Washington, DC. Its mission is to advance science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators, and the broader R&D community. The organization is governed by a Board of Directors drawn from all member companies, currently led by Chair Philip Floyd, Ph.D. (AbbVie), with day-to-day administration handled by a Secretariat operated by the law firm Faegre Drinker Biddle & Reath LLP.

The consortium operates a membership-based model in which any corporation or subsidiary significantly engaged in developing new chemical entities or new molecular entities (defined as sponsoring at least one active Clinical Trial Application) is eligible to join. Its core offerings are: (i) a sustained forum for the exchange of ideas across member companies, (ii) collaborative research programs that generate cross-functional data sets and scientific positions broader than any single member could produce, and (iii) a publications portfolio — peer-reviewed papers, white papers, and assessment tools — addressing topics such as immunogenicity risk assessment for nucleic acid therapeutics, science- and risk-based stability strategies, recovery animals in toxicology, and CRO animal care use program assessment. The consortium also engages global regulators, professional organizations, academic researchers, and government research institutes to build consensus on innovation and quality in pharmaceutical development.

IQ is funded through annual membership dues that are not publicly disclosed, operates with internal staff of 11-50 (with scientific work largely contributed in-kind by member companies), and maintains a global footprint through its membership roster — which spans large-cap pharma (e.g., AbbVie, Pfizer, Merck, Novartis, J&J, Lilly, Roche, GSK, AstraZeneca, Sanofi, Takeda), specialty biotech (e.g., Alnylam, Biogen, BioMarin, Vertex, Regeneron, Moderna), and emerging players (e.g., Avidity Biosciences, Callio Therapeutics, Kymera, Sironax USA) along with the Bill & Melinda Gates Medical Research Institute.

Name

IQ Consortium

Legal name

IQ Consortium

Website

https://iqconsortium.org

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

IQ Consortium is a not-for-profit industry consortium of 58 pharmaceutical and biotechnology companies that conducts collaborative pre-competitive research, publishes peer-reviewed scientific outputs, and engages global regulators to advance pharmaceutical development science and harmonization, funded through annual membership dues.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Consortium

NAICS

Professional Organizations (81392), Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Technical Committees, Working Groups & Expert Panels (BPADANAB)

akta.pro secondary industry

Executive Summits & Invitation-Only Forums (MPAGAGAK)

Keywords

• Pharmaceutical consortium
• Drug development research
• Biotechnology collaboration
• Regulatory science
• Industry publications

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Membership Dues: IQ Consortium generates revenue through membership fees paid by pharmaceutical and biotechnology companies. Members gain access to a sustained forum for exchange of ideas, collaborative research opportunities, industry surveys, benchmarking exercises, and external collaborations with governmental bodies, trade groups, and academic researchers.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

IQ Consortium is a not-for-profit organization of pharmaceutical and biotechnology companies that operates a membership-based collaborative research consortium. It enables member companies to jointly develop cross-functional data sets, scientific positions, and consensus recommendations on pharmaceutical development topics, and shares the results via peer-reviewed publications, industry surveys, benchmarking exercises, scientific conferences, and roundtables.

Product overview

IQ Consortium is a not-for-profit organization of pharmaceutical and biotechnology companies organized as a collaborative consortium rather than a traditional product company. The consortium offers scientific publications and research papers on pharmaceutical development topics, assessment tools for Contract Research Organizations, reference documents for laboratory animal studies, and a membership program providing access to collaborative research forums, industry surveys, benchmarking exercises, conferences, workshops, and roundtables. The portfolio consists of publications (peer-reviewed papers and white papers), tools (statistical planning worksheets, animal care assessment tools), and membership services for the pharmaceutical and biotechnology R&D community.

Differentiator

Problem solved

Functional benefit

Products and services

• IQ Consortium Membership Program Membership program providing pharmaceutical and biotechnology companies with access to a sustained forum for exchange of ideas, collaborative research participation, industry surveys, benchmarking exercises, and external collaborations with governmental bodies, trade groups, and academic researchers.
• IQ Publications Scientific publications hub featuring peer-reviewed research and white papers on pharmaceutical development topics including immunogenicity risk assessment, toxicology best practices, stability strategies, and biopharmaceutical comparability, available to member companies and the broader R&D community.
• IQ Statistics Meeting Prep Sheet Worksheet to help scientists prepare for meetings with statisticians prior to protocol development and in vivo study design, provided by the IQ Consortium.
• Comprehensive Animal Care Use Program Assessment Tool for CROs Comprehensive animal care use program assessment tool for Contract Research Organizations, developed by the IQ 3Rs Translational and Predictive Sciences group.
• Low-Risk Animal Care Use Program Assessment Tool for CROs Low-risk variant of the animal care use program assessment tool for Contract Research Organizations, developed by IQ 3Rs Translational and Predictive Sciences.
• Recommended Dose Volumes for Common Laboratory Animals Guidance document providing dose volume recommendations for common laboratory animals in pharmaceutical research studies.

Quantifiable outcome

• 58 member companies participating in collaborative research and industry initiatives

Named customers55 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and major.

• Faegre Drinker Biddle & Reath LLPcoreOthers
• Global Professional OrganizationsmajorStrategic or Co-development Partner
• Academic ResearchersmajorStrategic or Co-development Partner
• Government Research InstitutesmajorStrategic or Co-development Partner
• Other Industry ConsortiamajorStrategic or Co-development Partner

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Critical Path Institute (C-Path): Non-profit organization working with FDA, EMA, and industry to accelerate drug development through consortia and regulatory science. Closely aligned with IQ's regulatory-engagement and consensus-building model.
• Drug Information Association (DIA): Global life sciences industry association for regulatory, drug development, and knowledge exchange. Comparable membership model and pharma R&D focus with industry working groups, conferences, and publications.
• TransCelerate BioPharma: Non-profit consortium of pharma companies focused on clinical trial collaboration and R&D efficiency. Closely comparable to IQ Consortium in structure (membership-based, recurring dues revenue, member-driven working groups) and in mission (cross-industry scientific collaboration in pharma R&D).
• ISPE (International Society for Pharmaceutical Engineering): Global non-profit association for pharmaceutical engineering and manufacturing professionals. Similar mission of advancing pharma science through member collaboration, working groups, and publications.
• BioPhorum: Industry consortium serving biopharmaceutical manufacturers and suppliers through collaborative working groups and best-practice sharing. Mirrors IQ's cross-company working-group structure and member subscription model.
• Pistoia Alliance: Global, non-profit alliance of life sciences R&D organizations focused on collaborative innovation. Comparable to IQ as a member-driven industry consortium producing shared frameworks, publications, and pre-competitive outputs.
• CDISC (Clinical Data Interchange Standards Consortium): Standards-development organization for clinical research data with strong pharma industry membership. Overlaps with IQ's standards and consensus-building work for pharma R&D, including regulatory-aligned data standards.

Regional players

• EFPIA: European pharma industry association representing major European pharmaceutical companies. Comparable membership model to IQ but focused on a different geography (Europe) and on policy/advocacy rather than scientific collaboration.

Broad incumbents

• PhRMA: US pharma industry trade association representing major pharmaceutical companies. Similar member base to IQ Consortium but focused on policy/advocacy rather than scientific collaboration.
• BIO (Biotechnology Innovation Organization): Large US trade association representing the entire biotechnology industry. Broader scope than IQ but a comparable membership-driven advocacy, policy engagement, and conference model for pharma/biotech.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/iqconsortium

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IQ Consortium